Abstract library

323 results for "type 3 g-NET".
#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations
Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr Anguraj Sadanandam
Authors:
#2125 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: 400 Cases of Multicenter Retrospective Analysis
Introduction: Definitions of Type 3 gastric NEN (g-NEN) in ENETS Guidelines 2012 and 2016 are ambiguous and controversial, so Four-type classification has been proposed in China.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Huang-Ying Tan
Authors:
#1584 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: An Analysis of 241 Cases
Introduction: Definition of type 3 gastric NEN in 2012 and 2016 ENETS guidelines is not clear, so Four-type classification has been proposed.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Prof. Huang-Ying Tan
Authors:
Keywords: gastric nen, subtype
#1287 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: Experiences in 116 Chinese Patients
Introduction: Gastric NEN are a heterogeneous group of tumors.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors:
Keywords: gastric nen, type 1
#2134 Clinicopathological Features of 63 Cases with Type 3 Gastric Neuroendocrine Tumors
Introduction: Well-differentiated gastric neuroendocrine tumors (g-NET) are divided into three distinct types (type 1, type 2 and type 3),there are few studies on the clinicopathologic features of type 3 g-NET.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Huang-Ying Tan
Authors:
#160 The role of T-type calcium channels in medullary thyroid carcinoma (MTC): T-type calcium channel blockers inhibit hormone secretion and induce apoptotic cell death in a human MTC cell line
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5-10% of thyroid cancers. In the case of tumors limited to the thyroid gland, the prognosis is generally favorable, whereas 5-year survival averages only 40% in patients with metastatic disease. In these patients, conventional chemotherapy only occasionally leads to a complete response and partial responses are observed in less than 30% of the cases. Therefore, intense efforts are currently directed toward the identification of new druggable targets for the treatment of this devastating disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Rosario Pivonello
Authors:
#295 Unusual Behavior of Gastric Carcinoid Type 1
Introduction: Gastric carcinoids (GC) are rare tumors of the stomach. GC type 1 are associated with chronic atrophic gastritis (CAG) and are the most benign type, having low metastatic potential.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Matilde P Spampatti
Authors:
#763 Endoscopic Therapy with Argon Plasma Coagulation for Multiple Type 1 Gastric Carcinoid Tumors
Introduction: Data regarding Type I gastric carcinoids and their evolution in prospective series are scarce, thus treatment and follow-up are not codified.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Rodrigo Castano
Authors:
#1593 Role of SSA in the Management of Multiple Type 1 Gastric Neuroendocrine Neoplasms
Introduction: Type 1 g-NENs associated with autoimmune chronic atrophic gastritis have high risk of recurrence but rare metastasis. Most type 1 patients are managed by endoscopic approach. The clinical benefit of somatostatin analogues (SSA) for type 1 g-NENs is controversial.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Prof. Huang-Ying Tan
Authors:
Keywords: SSA, gastric nen, type 1
#1673 Hsa-microRNA-202-3p Up-regulated in Type 1 Gastric Neuroendocrine Neoplasms
Introduction: Type 1 gastric neuroendocrine neoplasm (g-NENs) is a kind of rare malignant tumor. The molecular mechanism of this disease is unknown. MicroRNA (miRNA) plays important roles in the occurrence and development of tumors. At present, research about the role of miRNA in type 1 g-NENs is quite few.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Prof. Huang-Ying Tan
Authors: